Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
07 mars 2023 07h00 HE
|
Voyager Therapeutics, Inc.
- Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACER™ novel capsid platform through transactions with Pfizer and Novartis - -...
Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
06 mars 2023 07h00 HE
|
Voyager Therapeutics, Inc.
Options exercised on two targets; Voyager eligible to receive associated development, regulatory, and commercial milestones, plus tiered royalties With option exercise, potential to expand agreement...
Voyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
28 févr. 2023 07h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics to Participate in Upcoming Investor Conferences
09 févr. 2023 07h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 janv. 2023 16h01 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases
09 janv. 2023 07h00 HE
|
Voyager Therapeutics, Inc.
- Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial...
Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 07h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
14 déc. 2022 07h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 nov. 2022 16h01 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
08 nov. 2022 07h00 HE
|
Voyager Therapeutics, Inc.
- Voyager’s TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER - - Pipeline programs...